November 2023 - Page 5 of 5

MondayNov 06, 2023 9:00 am

Renovaro Biosciences Inc. (NASDAQ: RENB) Announces Three New Members to Board of Directors as Definitive Agreement with GEDiCube Announced

Renovaro added Avram Miller, Leni Boeren, Ruud Hendriks, to the company's board of directors The three additions bring extensive financial backgrounds that will help as the company ventures into the new agreement with GEDiCube and Renovaro AI branding Avram Miller believes that Renovaro Bioscience, combined with GEDiCube, has the key elements to play a significant role in transforming AI's impact on medicine Renovaro Biosciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors with short life expectancy, recently announced a definitive agreement to combine with the advanced AI Company GEDiCube Intl Ltd., rebranding…

FridayNov 03, 2023 9:45 am

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) CEO Interviewed for New to the Street Segment Regarding Fines for Bank Privacy Violations

U.S. regulatory agencies are fining banks and other financial institutions millions of dollars for privacy violations Fines range up to $50 million per occurrence, but Sekur’s services offer an immediate and cost-effective solution to avoid fines Sekur offers Chat-by-Invite, SekurMessenger, and SekurMail as a fully encrypted communications platform that financial institutions can utilize to safeguard their data and comply with U.S. regulations Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, was recently featured on the New to the Street segment “Sekur Privacy & Sekur Security…

FridayNov 03, 2023 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) PRV Sale Prospects Strengthened by Recent Industry Developments

PaxMedica, with the help of financial services firm Bourne Partners, is actively exploring presale of its Priority Review Voucher (“PRV”), highly valuable in the pharmaceutical marketplace once it gets formal approval from the FDA The move is the next step in PaxMedica's ongoing commitment to advancing innovative healthcare solutions for autism patients worldwide Similar successful endeavors in the pharmaceutical landscape have demonstrated lucrative potential PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has set its sights on an exciting potential opportunity. With the engagement of Bourne Partners, a prominent financial services firm specializing in…

ThursdayNov 02, 2023 9:45 am

D-Wave Quantum Inc. and Satispay Build Quantum Hybrid Application Designed to Optimize Customer Rewards Initiatives

Application showed an improvement of 50% in customer rewards program effectiveness for the same amount of budget Italian fintech company Satispay anticipates that its internal teams will use the application weekly when the company transitions it into production D-Wave’s suite of services is backed by two decades of quantum technology development and over ten years of customer feedback, which have been incorporated to create the industry’s first quantum computer designed for commercial business applications D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, recently announced that it…

ThursdayNov 02, 2023 9:00 am

SenesTech Inc. (NASDAQ: SNES) Webcast at Lytham Fall Investor Conference Highlights Company’s Innovation and Growth with New Solution for Rodent Control

Rat populations have created concerns for centuries because of their potential to be a vector for diseases, their destruction of infrastructure, and their consumption or spoilage of stored food supplies Arizona-based SenesTech Inc. is now introducing its new Evolve(TM) Soft Bait as a companion to its patented ContraPest(R) liquid product as means of shifting rodent control methods from lethal poisons to preventative birth control formulations, with Evolve(TM) Soft Bait representing a big step into a major new market The company recently discussed its operation and plans for the near future during a webcast presentation as part of Lytham Partners’ Fall…

WednesdayNov 01, 2023 9:45 am

Insights and Opportunities Unfold as the 2023 New Orleans Investment Conference Kicks Off

Serious investors — and anyone concerned with protecting and building wealth in volatile times — invited to attend the New Orleans Investment Conference to be held in New Orleans, November 1-4, 2023. With a rich legacy spanning almost 50 years, the New Orleans Investment Conference has been acclaimed as “The Greatest Investment Show on Earth” by Money Magazine. Held in the heart of New Orleans, the 2023 Conference is set to present a dream team of world-class experts on geopolitics, macroeconomics and every asset class to hundreds of savvy investors. The 2023 Conference will feature enlightening presentations from leading experts…

WednesdayNov 01, 2023 9:00 am

SuperCom Ltd. (NASDAQ: SPCB) Eyes the Growing World Market for Domestic Violence Offender Monitoring Solutions

The UK’s criminal justice department recently announced that domestic abusers leaving prison will be wearing electronic monitoring tags for better victim protection Up to 500 offenders will be forced to wear GPS and curfew tags to monitor their movements, with those who breach the stipulated license conditions being returned to prison This move by the UK validates digital monitoring solutions such as SuperCom’s Electronic Monitoring (“EM”) products It also shows the technology’s viability in solving emerging issues while also validating SuperCom’s research and development efforts as targeting an active and growing world market SuperCom (NASDAQ: SPCB), a global provider of…

WednesdayNov 01, 2023 9:00 am

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

NetworkNewsWire Editorial Coverage: GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of drugs in lieu of conventional weight-loss procedures. There is a growing body of clinical evidence showing GLP-1 agonists safely control blood sugar (glucose) levels and deliver tremendous positive outcomes, such as a recent New England Journal of Medicine study reporting weight loss of 49 to 52 pounds. As good as GLP-1 agonist are, they can get better, which is part of the mission of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), a global innovator in drug-delivery platforms.…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

Month: November 2023